Affimed (AFMD)
(Real Time Quote from BATS)
$5.44 USD
+0.41 (8.15%)
Updated Apr 29, 2024 03:32 PM ET
2-Buy of 5 2
F Value F Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AFMD 5.44 +0.41(8.15%)
Will AFMD be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for AFMD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AFMD
Wall Street Analysts Believe Affimed N.V. (AFMD) Could Rally 146.73%: Here's is How to Trade
Affimed N.V. (AFMD) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
AFMD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Does Affimed N.V. (AFMD) Have the Potential to Rally 263.36% as Wall Street Analysts Expect?
Affimed N.V. (AFMD) Upgraded to Buy: Here's What You Should Know
Seer, Inc. (SEER) Reports Q4 Loss, Tops Revenue Estimates
Other News for AFMD
Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology
Biotech Alert: Searches spiking for these stocks today
Affimed price target raised by $4 at Stifel, here's why
Truist Financial Sticks to Its Buy Rating for Affimed (AFMD)
Promising Clinical Trials and Strategic Financial Management Affirm Buy Rating for Affimed